/C O R R E C T I O N -- Decoy Therapeutics, Inc/

In the news release, Decoy Therapeutics Exploring Pan-Filovirus Program via FDA Animal Rule Pathway and Non-Dilutive Funding, issued 22-Sep-2026 by Decoy Therapeutics, Inc over PR Newswire, we are advised by the company that the original version contained incorrect information introduced by PR Newswire during transmission. The complete, corrected release follows, with additional details at the end: Decoy Therapeutics Exploring Pan-Filovirus Program via FDA Animal Rule Pathway and Non-Dilutive Funding

Next-Generation D-MAVs™ Demonstrate Potent In Vitro Activity Against Ebola Zaire and Marburg Viruses; Targeting High-Value FDA Priority Review Voucher Eligibility